Nanoparticle delivery through the BBB in central nervous system tuberculosis

Griego, Anna; Scarpa, Edoardo; Matteis, Valeria De; Rizzello, Loris

doi:10.1002/ibra.12087

Cited by 2 publications

(2 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nanoparticles have demonstrated effective treatments and encouraging results for TB treatment due to several advantages over conventional therapy [75][76][77][78] (Figure 2). Numerous types of nanocarriers have been effective in drug delivery systems for a wide range of administration methods [79][80][81][82][83][84].…”

Section: Nanotechnological Approach For Combating Tb 41 Nanotechnolog...mentioning

confidence: 99%

An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management

et al. 2023

View full text Add to dashboard Cite

Tuberculosis (TB), one of the deadliest contagious diseases, is a major concern worldwide. Long-term treatment, a high pill burden, limited compliance, and strict administration schedules are all variables that contribute to the development of MDR and XDR tuberculosis patients. The rise of multidrug-resistant strains and a scarcity of anti-TB medications pose a threat to TB control in the future. As a result, a strong and effective system is required to overcome technological limitations and improve the efficacy of therapeutic medications, which is still a huge problem for pharmacological technology. Nanotechnology offers an interesting opportunity for accurate identification of mycobacterial strains and improved medication treatment possibilities for tuberculosis. Nano medicine in tuberculosis is an emerging research field that provides the possibility of efficient medication delivery using nanoparticles and a decrease in drug dosages and adverse effects to boost patient compliance with therapy and recovery. Due to their fascinating characteristics, this strategy is useful in overcoming the abnormalities associated with traditional therapy and leads to some optimization of the therapeutic impact. It also decreases the dosing frequency and eliminates the problem of low compliance. To develop modern diagnosis techniques, upgraded treatment, and possible prevention of tuberculosis, the nanoparticle-based tests have demonstrated considerable advances. The literature search was conducted using Scopus, PubMed, Google Scholar, and Elsevier databases only. This article examines the possibility of employing nanotechnology for TB diagnosis, nanotechnology-based medicine delivery systems, and prevention for the successful elimination of TB illnesses.

show abstract

Section: Nanotechnological Approach For Combating Tb 41 Nanotechnolog...mentioning

confidence: 99%

An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Furthermore, the recent reports on D29 [29,30] and Ms6 Lysin B [31] have provided promising evidence supporting LysinB as a new therapeutic strategy.…”

Section: Introductionmentioning

confidence: 99%

A novel LysinB from an F2 sub-cluster mycobacteriophageRitSun

Arora,

Nadar,

Bajpai

2024

Preprint

View full text Add to dashboard Cite

With the growing antibiotic resistance in mycobacterial species posing a significant threat globally, there is an urgent need to find alternative solutions. Bacteriophage-derived endolysins aid in releasing phage progeny from the host bacteria by attacking the cell wall at the end of their life cycle. Endolysins are attractive antibacterial candidates due to their rapid lytic action, specificity and low risk of resistance development. In mycobacteria, owing to the complex, hydrophobic cell wall, mycobacteriophages usually synthesize two endolysins: LysinA, which hydrolyzes peptidoglycan; LysinB, which delinks mycolylarabinogalactan from peptidoglycan and releases mycolic acid. In this study, we conducted domain analysis and functional characterization of a recombinant LysinB from RitSun, an F2 sub-cluster mycobacteriophage. Several properties of RitSun LysinB are important as an antimycobacterial agent: its ability to lyse Mycobacterium smegmatis "from without", a specific activity of 1.36 U/mg, higher than the reported ones and its inhibitory effect on biofilm formation. Given the impervious nature of the mycobacterial cell envelope, native endolysins ability to damage cells on exogenous applications warrants further investigation. A molecular dissection of RitSun LysinB to identify its cell wall destabilizing sequence could be utilized to engineer other native lysins as fusion proteins and expand their activity profile.

show abstract

Nanoparticle delivery through the BBB in central nervous system tuberculosis

Cited by 2 publications

References 140 publications

An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management

An Insight into Advances in Developing Nanotechnology Based Therapeutics, Drug Delivery, Diagnostics and Vaccines: Multidimensional Applications in Tuberculosis Disease Management

A novel LysinB from an F2 sub-cluster mycobacteriophageRitSun

Contact Info

Product

Resources

About